Tagged Articles

pancreatic diseases 4 articles

Genetic mutation associated with cancer more likely in type 2 diabetics

People with a genetic abnormality associated with cancer are more likely to have type 2 diabetes, according to a new study published in the journal Nature Genetics. Type 2 diabetics are already at higher risk of developing cancer, especially blood cancers like lymphoma and leukemia. The new study suggests that gene mutations known as clonal mosaic events, or CMEs, may be source of the problem. CMEs occur when cells have extra copies or missing copies of DNA. They are rarely seen in younger people but are more likely to occur as people age. Previous research has shown that people with ... Read More

Diabetes drug Tradjenta linked to acute pancreatitis, fatal pancreatitis

The safety label for the type 2 diabetes treatment Tradjenta (linagliptin) has been updated to warn that there have been reports of acute pancreatitis, including fatal pancreatitis, in patients taking the medication. Doctors and patients are advised to take special note of potential signs and symptoms of pancreatitis, and if the condition is suspected, to discontinue Tradjenta and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at an increased risk for developing the condition while using the drug. Tradjenta is an oral medication that is designed to reduce blood sugar levels in patients with ... Read More

Lifestyle intervention does not reduce risk of heart attacks, strokes in type 2 diabetics

A controlled diet and exercise plan may help patients with type 2 diabetes lose weight, but the weight loss did not reduce their risk for having heart problems, a new study shows. The study, sponsored by the National Institutes of Health (NIH), looked at the long-term effects of healthy nutrition and exercise in overweight people with type 2 diabetes. More than 5,000 obese adults ages 45 to 76 with type 2 diabetes were followed for nearly 10 years. Half of the participants focused on lifestyle intervention through physical activity and low calorie intake, and the other half was given conventional ... Read More

Roche stops development of type 2 diabetes drug because of safety, efficacy concerns

Drug maker Roche has stopped development of the experimental type 2 diabetes treatment aleglitazar because of undesirable side effects and a lack of efficacy. The decision was based on a recommendation by the independent Data and Safety Monitoring Board, which conducted a regular safety review of the aleglitazar AleCardio phase III trail. The drug was being tested in patients with a recent acute coronary syndrome event and type 2 diabetes. Patients reportedly suffered from side effects to the kidneys and the heart. “The safety of patients is our first priority. Roche is working with investigators to support the management of ... Read More